bisnoryangonin: extract from mushrooms [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 54680478 |
| CHEMBL ID | 4066356 |
| CHEBI ID | 29547 |
| SCHEMBL ID | 13660630 |
| MeSH ID | M0040372 |
| Synonym |
|---|
| yangonin, bis-nor- |
| bisnoryangonin |
| nsc212501 |
| nsc-212501 |
| 13709-27-8 |
| bis-noryangonin |
| AC1NQZFH , |
| 4-hydroxy-6-(4-hydroxystyryl)-2-pyrone |
| CHEBI:29547 |
| SCHEMBL13660630 |
| 4-hydroxy-6-[(e)-2-(4-hydroxyphenyl)vinyl]pyran-2-one |
| (e)-6-(4-hydroxystyryl)-4-hydroxy-2h-pyran-2-one |
| (e)-4-hydroxy-6-(4-hydroxystyryl)-2h-pyran-2-one |
| Q27110139 |
| CHEMBL4066356 |
| 4-hydroxy-6-[(e)-2-(4-hydroxyphenyl)ethenyl]pyran-2-one |
| EN300-28226426 |
| 4-hydroxy-6-[(e)-2-(4-hydroxyphenyl)ethenyl]-2h-pyran-2-one |
| DTXSID301038265 |
| Z2740389838 |
| Class | Description |
|---|---|
| styrenes | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| resveratrol biosynthesis | 0 | 9 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1489216 | Inhibition of Tdp1 (unknown origin) up to 40 uM using 5'-(6-TAMN-AGGATCTAAAAGACTT-BHQ-)3' as substrate pretreated for 30 mins followed by substrate addition by fluorescence assay | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17 | Achyrodimer F, a tyrosyl-DNA phosphodiesterase I inhibitor from an Australian fungus of the family Cortinariaceae. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||